flow trial semaglutide all-cause mortality hazard ratio Long-term kidney outcomes of in obesity and cardiovascular disease in the SELECT Semaglutide Effects of Semaglutide on Chronic

Additionally, Doustdar said that Novos obesity pipeline will remain highly competitive, pointing to the companys triple-agonist candidate UBT251 and saying that early comparative data appear favorable against Lillys Retatrutide

Use sterile equipment

Stroke associated with giant cell arteritis: a population-based study

GLP-1 therapies have already shown efficacy in reducing major adverse cardiovascular events and slowing kidney disease progression in people with diabetes and obesity

The benefits of treating obesity often outweigh age-related concerns

"It's the same mindset I have used in everything I've ever done, to just say, 'actually I want to help, make a product that can help' either in society, or people with disease," she said